 Home > Active Ingredient News > Antitumor Therapy > JCO: The impact of intensive drug intervention on the safety of new oral anticancer drugs and the prognosis reported by patients

JCO: The impact of intensive drug intervention on the safety of new oral anticancer drugs and the prognosis reported by patients

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

remodulin side effects

ketamine medication

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Oral anticancer drugs (such as kinase inhibitors) play an important role in cancer treatment.

Oral anticancer drugs are facing severe challenges in terms of drug safety, and many factors that limit the benefits of oral anticancer drugs have been recognized.

Eating may increase and reduce the absorption of these drugs

AMBORA is a randomized, multi-center study that included patients with solid tumors who were treated with anti-cancer drugs approved in 2001 and later.

Primary study endpoint

A total of 202 patients were recruited, and the intervention group had significantly fewer anti-tumor drug-related problems than the control group (3.

The intervention group had significantly fewer problems related to anti-tumor drugs than the control group, and the treatment satisfaction of patients in the intervention group was significantly higher.

Incidence of composite endpoint

The risk ratio of the combined endpoints of serious adverse reactions (≥3 grade), treatment interruption, unplanned hospitalization, and death in the intervention group and the control group was 0.

The risk ratio of the combined endpoints of the intervention group and the control group for serious adverse reactions (≥3 grade), treatment interruption, unplanned hospitalization, and death was 0.

Intensified clinical pharmacology/drug therapy has a considerable positive impact on the number of medication errors, the patient's treatment consciousness and serious side effects

Original source:

Dürr Pauline, Schlichtig Katja, Kelz Carolin et al.

org/10.
1200/JCO.
20.
03088" target="_blank" rel="noopener">The Randomized AMBORA Trial: Impact of Pharmacological / Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.